Mucinex® for Treatment of Filamentary Keratitis

Description

It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Study Start Date

September, 01 2016

Estimated Completion Date

July 2018

Interventions

  • Drug: Mucinex®

Study ID

Massachusetts Eye and Ear Infirmary -- 16-044H

Status

Recruiting

Trial ID

NCT02859246

Study Type

Interventional

Trial Phase

N/A

Enrollment Quota

15

Sponsor

Massachusetts Eye and Ear Infirmary

Inclusion Criteria

  • Patients with filamentary keratitis
  • 18 years and older

Exclusion Criteria

  • Active ocular surface infection of any type
  • Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones
  • Schirmer's test<3mm
  • History of hypersensitivity to Mucinex®
  • Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

Gender

All

Ages

18 Years to 80 Years

Accepts Healthy Volunteers

No

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Massachusetts Eye and Ear Infirmary - Boston, Massachusetts 2.8 miles Vijeeta Tadla 617-573-6060 opthalmologyclinicalresearch@meei.harvard.edu

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.